Azathioprine versus comparator
| Azathioprine | Placebo | OR (95% CI) | |||
| Events | Total | Events | Total | ||
| Azathioprine versus placebo (all contexts) | 21 | 438 | 1 | 504 | 8.92 (2.61 to 30.54) p=0.0005 |
| Azathioprine versus placebo (active disease—medical) | 11 | 200 | 0 | 210 | 8.30 (1.44 to 47.71) p=0.02 |
| Azathioprine versus placebo (maintenance of remission—medical) | 10 | 198 | 1 | 253 | 9.58 (1.70 to 54.08) p=0.01 |
| Azathioprine versus placebo (maintenance of remission—surgical) | 0 | 40 | 0 | 41 | – |
| Azathioprine | Mesalazine | OR (95% CI) | |||
| Events | Total | Events | Total | ||
| Azathioprine versus mesalazine (all contexts) | 11 | 207 | 1 | 199 | 3.42 (0.85 to 13.780) p=0.08 |
| Azathioprine versus mesalazine (active disease—medical) | 1 | 36 | 0 | 36 | 3.08 (0.12 to 78.27) p=0.49 |
| Azathioprine versus mesalazine (maintenance of remission—medical) | – | – | – | – | – |
| Azathioprine versus mesalazine (maintenance of remission—surgical) | 10 | 171 | 1 | 163 | 3.46 (0.67 to 17.93) p=0.14 |
| Azathioprine | Budesonide | OR (95% CI) | |||
| Events | Total | Events | Total | ||
| Azathioprine versus budesonide (all contexts) | 2 | 38 | 0 | 39 | 5.41 (0.25 to 116.51) p=0.28 |
| Azathioprine versus budesonide (active disease—medical) | – | – | – | – | – |
| Azathioprine versus budesonide (maintenance of remission—medical) | 2 | 38 | 0 | 39 | 5.41 (0.25 to 116.51) p=0.28 |
| Azathioprine versus budesonide (maintenance of remission—surgical) | – | – | – | – | – |
| Azathioprine | Infliximab | OR (95% CI) | |||
| Events | Total | Events | Total | ||
| Azathioprine versus infliximab (all contexts) | 0 | 181 | 0 | 180 | – |
| Azathioprine versus infliximab (active disease—medical) | 0 | 169 | 0 | 170 | – |
| Azathioprine versus infliximab (maintenance of remission—medical) | – | – | – | – | – |
| Azathioprine versus infliximab (maintenance of remission—surgical) | 0 | 11 | 0 | 11 | – |
| Azathioprine | Adalimumab | OR (95% CI) | |||
| Events | Total | Events | Total | ||
| Azathioprine versus adalimumab (all contexts) | 1 | 56 | 0 | 61 | 3.00 (0.11 to 79.13) p=0.51 |
| Azathioprine versus adalimumab (active disease—medical) | – | – | – | – | – |
| Azathioprine versus adalimumab (maintenance of remission—medical) | – | – | – | – | – |
| Azathioprine versus adalimumab (maintenance of remission—surgical) | 1 | 56 | 0 | 61 | 3.00 (0.11 to 79.13) p=0.51 |
| Azathioprine | Methotrexate | OR (95% CI) | |||
| Events | Total | Events | Total | ||
| Azathioprine versus methotrexate (all contexts) | 1 | 27 | 0 | 27 | 3.11 (0.12 to 79.87) p=0.49 |
| Azathioprine versus methotrexate (active disease—medical) | 1 | 27 | 0 | 27 | 3.11 (0.12 to 79.87) p=0.49 |
| Azathioprine versus methotrexate (maintenance of remission—medical) | – | – | – | – | – |
| Azathioprine versus methotrexate (maintenance of remission—surgical) | – | – | – | – | – |
Incidence of pancreatitis.